IgG antibodies mediated gold nanoparticles conjugated to methotrexate as targeted chemotherapy for lung cancer

References

• Baker A, Wahid I, Hassan Baig M, et al. Silk cocoon-derived protein bioinspired gold nanoparticles as a formidable anticancer agent. J Biomed Nanotechnol. 2021;17(4):615–626. doi: 10.1166/jbn.2021.3053.
   PubMed Web of Science ®Google Scholar
• Crous A, Abrahamse H. Effective gold nanoparticle-antibody-mediated drug delivery for photodynamic therapy of lung cancer stem cells. Int J Mol Sci. 2020;21:3742. doi: 10.3390/ijms21113742.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Tamura K, Naito Y, et al. Patient perceptions of symptoms and concerns during cancer chemotherapy:‘affects my family’is the most important. Int J Clin Oncol. 2017;22(4):793–800. doi: 10.1007/s10147-017-1117-y.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang X, Wang B, et al. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. Adv Drug Deliv Rev. 2022;190:114525. doi: 10.1016/j.addr.2022.114525.
   PubMed Web of Science ®Google Scholar
• Scicluna MC, Vella-Zarb L. Evolution of nanocarrier drug-delivery systems and recent advancements in covalent organic framework–drug systems. ACS Appl Nano Mater. 2020;3(4):3097–3115. doi: 10.1021/acsanm.9b02603.
   Web of Science ®Google Scholar
• Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer, trends. Trends Pharmacol Sci. 2009;30(11):592–599. doi: 10.1016/j.tips.2009.08.004.
   PubMed Web of Science ®Google Scholar
• Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. J Nanomater. 2019;2019:1–26. doi: 10.1155/2019/3702518.
   Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25. doi: 10.1016/j.addr.2013.11.009.
   PubMed Web of Science ®Google Scholar
• Mack F, Ritchie M, Sapra P. The next generation of antibody drug conjugates. Semin Oncol. 2014;41(5):637–652. doi: 10.1053/j.seminoncol.2014.08.001.
   PubMed Web of Science ®Google Scholar
• Heemskerk N, Gruijs M, Temming AR, et al. Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity. J Clin Invest. 2021;131:e134680.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–370. doi: 10.1038/nrc3930.
   PubMed Web of Science ®Google Scholar
• Reis ES, Mastellos DC, Ricklin D, et al. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol. 2018;18(1):5–18. doi: 10.1038/nri.2017.97.
   PubMed Web of Science ®Google Scholar
• Chiossone L, Dumas P-Y, Vienne M, et al. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671–688. doi: 10.1038/s41577-018-0061-z.
   PubMed Web of Science ®Google Scholar
• Kaifu T, Nakamura A. Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review. Int Immunol. 2017;29(7):319–325. doi: 10.1093/intimm/dxx041.
   PubMed Web of Science ®Google Scholar
• Del Re M, Rofi E, Restante G, et al. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget. 2018;9(5):6630–6643. doi: 10.18632/oncotarget.23553.
   PubMedGoogle Scholar
• Moshera Samy, Sameh Hosam Abd El-Alim, Abd El Gawad Rabia, Amal Amin, Magdy M.H. Ayoub. Formulation, characterization and in vitro release study of 5-fluorouracil loaded chitosan nanoparticles. International Journal of Biological Macromolecules. 2020; 156: 783-791. doi: 10.1016/j.ijbiomac.2020.04.112.
   Google Scholar
• Bedenic B, Topic M, Budimir A, et al. Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model. Chemotherapy. 2006;52(6):293–297. doi: 10.1159/000095969.
   PubMed Web of Science ®Google Scholar
• Ayyappan S, Sundaraganesan N, Aroulmoji V, et al. Molecular structure, vibrational spectra and DFT molecular orbital calculations (TD-DFT and NMR) of the antiproliferative drug methotrexate. Spectrochim Acta A Mol Biomol Spectrosc. 2010;77(1):264–275. doi: 10.1016/j.saa.2010.05.021.
   PubMed Web of Science ®Google Scholar
• Baker A, Khalid M, Uddin I, et al. Targeted non AR mediated smart delivery of abiraterone to the prostate cancer. PLOS One. 2022;17(8):e0272396. doi: 10.1371/journal.pone.0272396.
   PubMed Web of Science ®Google Scholar
• Iram S, Zahera M, Khan S, et al. Gold nanoconjugates reinforce the potency of conjugated cisplatin and doxorubicin. Colloids Surf B Biointerfaces. 2017;160:254–264. doi: 10.1016/j.colsurfb.2017.09.017.
   PubMed Web of Science ®Google Scholar
• Nachin L, Nannmark U, Nyström T. Differential roles of the universal stress proteins of Escherichia coli in oxidative stress resistance, adhesion, and motility. J Bacteriol. 2005;187(18):6265–6272. doi: 10.1128/JB.187.18.6265-6272.2005.
   PubMed Web of Science ®Google Scholar
• Baker A, Syed A, Iram S, et al. AR independent anticancer potential of enza against prostate cancer. Colloids Surfaces A Physicochem Eng Asp. 2022;642:128598. doi: 10.1016/j.colsurfa.2022.128598.
   Web of Science ®Google Scholar
• Zhou Y, Andersson O, Lindberg P, et al. Reversible hydrophobic barriers introduced by microcontact printing: application to protein microarrays. Microchim Acta. 2004;146(3–4):193–205. doi: 10.1007/s00604-003-0174-2.
   Web of Science ®Google Scholar
• Baker A, Syed A, Alyousef AA, et al. Sericin-functionalized GNPs potentiate the synergistic effect of levofloxacin and balofloxacin against MDR bacteria. Microb Pathog. 2020;148:104467. doi: 10.1016/j.micpath.2020.104467.
   PubMed Web of Science ®Google Scholar
• Berne BJ, Pecora R. Dynamic light scattering: with applications to chemistry, biology, and physics. Mineola: Courier Corporation; 2000.
   Google Scholar
• Rabinovich-Guilatt L, Couvreur P, Lambert G, et al. Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem Phys Lipids. 2004;131(1):1–13. doi: 10.1016/j.chemphyslip.2004.04.003.
   PubMed Web of Science ®Google Scholar
• McKie A, Samuel D, Cohen B, et al. A quantitative immuno-PCR assay for the detection of mumps-specific IgG. J Immunol Methods. 2002;270(1):135–141. doi: 10.1016/s0022-1759(02)00325-3.
   PubMed Web of Science ®Google Scholar
• Koźmiński P, Halik PK, Chesori R, et al. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int J Mol Sci. 2020;21:3483. doi: 10.3390/ijms21103483.
   PubMed Web of Science ®Google Scholar
• Senapati S, Mahanta AK, Kumar S, et al. Controlled drug delivery vehicles for cancer treatment and their performance, signal transduct. Target Ther. 2018;3:1–19.
   Google Scholar
• Nejadmoghaddam M-R, Minai-Tehrani A, Ghahremanzadeh R, et al. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11:3.
   PubMedGoogle Scholar
• Munisvaradass R, Kumar S, Govindasamy C, et al. Human CD3+ T-cells with the anti-ERBB2 chimeric antigen receptor exhibit efficient targeting and induce apoptosis in ERBB2 overexpressing breast cancer cells. Int J Mol Sci. 2017;18:1797. doi: 10.3390/ijms18091797.
   PubMed Web of Science ®Google Scholar
• Romig AD Jr, Baker AB, Johannes J, et al. An introduction to nanotechnology policy: opportunities and constraints for emerging and established economies. Technol Forecast Soc Change. 2007;74(9):1634–1642. doi: 10.1016/j.techfore.2007.04.003.
   Web of Science ®Google Scholar
• Barua S, Yoo J-W, Kolhar P, et al. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci U S A. 2013;110(9):3270–3275. doi: 10.1073/pnas.1216893110.
   PubMed Web of Science ®Google Scholar
• Abedin MR, Powers K, Aiardo R, et al. Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. Sci Rep. 2021;11(1):7347. ppdoi: 10.1038/s41598-021-86762-6.
   PubMed Web of Science ®Google Scholar
• Launay P, Patry C, Lehuen A, et al. Alternative endocytic pathway for immunoglobulin a Fc receptors (CD89) depends on the lack of FcRγ association and protects against degradation of bound ligand. J Biol Chem. 1999;274(11):7216–7225. doi: 10.1074/jbc.274.11.7216.
   PubMed Web of Science ®Google Scholar